PharmaGap Inc.’s lead cancer drug shrinks early-stage colon cancer tumours by 34% in recent testing on mice. The Ottawa-based company says that PhG-alpha-1 also increases the efficacy of chemotherapy in more advanced colon cancer. “We are delighted with this additional compelling evidence of efficacy seen with our lead compound in these most recent results. These cancers are both aggressive and representative of cancers found in real patients,” says PharmaGap CEO Robert McInnis. “These additional test results add to the body of evidence that PhG-alpha-1 has the potential to be developed into an effective agent against cancer in humans.” In April, the biopharmaceutical company reported encouraging results in treating breast cancer, as well as colon cancer.